A phase II antiemetic combination (COMD) for cisplatin-induced nausea and vomiting
- 1 September 1986
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 18 (1) , 88-89
- https://doi.org/10.1007/bf00253073
Abstract
Thirteen patients resistant to high-dose metoclopramide (≥5 emetic episodes in 24 h following chemotherapy) were treated in the subsequent course of CDDP chemotherapy with COMD (chlorpromazine, orphenadrine, metoclopramide, dexamethasone). A statistically significant reduction in the number of vomiting episodes was obtained, and 69% of patients showed a better acceptance of CDDP treatment. Subsequently, the same antiemetic combination was administered to 31 untreated patients receiving CDDP alone for the first time: 67.7% obtained complete protection from vomiting with minimal toxicity. According to our experience, COMD is an efficacious and well-tolerated antiemetic combination in cisplatin-treated patients; however, further studies with larger numbers of patients are required to confirm these preliminary results.This publication has 5 references indexed in Scilit:
- Evaluation of a combination antiemetic regimen including iv high-dose metoclopramide, dexamethasone, and diphenhydramine in cisplatin-based chemotherapy regimens.1985
- Combination antiemetic therapy in cisplatin-induced nausea and vomitingCancer, 1985
- Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patientsCancer, 1985
- Immediate termination of intractable vomiting induced by cisplatin combination chemotherapy using an intensive five-drug antiemetic regimen.1984
- MetoclopramideDrugs, 1983